Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
Expert Review of Clinical Pharmacology|November 13, 2025
Immunotherapy in biliary tract cancer: effective but not enough?Alessandro Rizzo, Enes Erul, Deniz Can Guven, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 12, 2021
Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapyDeniz Can Guven, Melek Seren Aksun, Taha Koray Sahin, et al.
Medicina (Kaunas, Lithuania)|April 26, 2025
Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) StudyZiya Kalkan, Senar Ebinc, Murat Arcagok, et al.
Medicina (Kaunas, Lithuania)|November 27, 2025
Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. <i>Medicina</i> 2025, <i>61</i>, 638Ziya Kalkan, Senar Ebinc, Murat Arcagok, et al.
International Journal of Cancer|September 9, 2022
Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapyDeniz Can Guven, Fatma Gul Gulbahce Incesu, Hasan Cagri Yildirim, et al.
BMJ Supportive & Palliative Care|July 16, 2020
COVID-19 pandemic: changes in cancer admissionsDeniz Can Guven, Burak Yasin Aktas, Melek Seren Aksun, et al.
Integrative Cancer Therapies|October 5, 2024
The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional StudyFatih Kus, Deniz Can Guven, Hasan Cagri Yildirim, et al.
Anti-Cancer Drugs|February 2, 2023
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitorsDeniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, et al.
Cancer Biomarkers : Section a of Disease Markers|December 27, 2021
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitorsDeniz Can Guven, Oktay Halit Aktepe, Melek Seren Aksun, et al.
Cancer Medicine|December 23, 2023
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) studyDeniz Can Guven, Musa Baris Aykan, Harun Muglu, et al.
Pageof 14